p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids)

Table 4 p21 and p27 expressions and clinicopathologic features (%)

Clinicopathologicfeature		p21	P3	p27	P3
Gender	Male	1.5	0.60	58.0	0.34
	Female	0.85		36.4
Localization	Fundus	3.0	< 0.05	90.5	< 0.05
	Other	0.7		34.2
Multifocality	Multifocal	0.7	0.57	45.7	0.92
	Single focus	1.25		42.9
NEH1	Present	1.0	0.842	50.8	0.64
	Absent	1.16		37.5
NED1	Present	0.7	0.57	45.7	0.80
	Absent	1.25		42.8
Atrophy	Atrophic	1.3	0.47	46.4	0.50
	Non-atrophic	0.8		32.5
Intestinal metaplasia	IM2 (+)	χ4	χ4	49.6	0.09
	IM2 (-)	X4		16.5
Submucosal extension	Present	1.0	0.893	49.3	0.67
	Absent	0.8		30.5
p27 immunoexpression	p21 expressing	χ4	χ4	68.0	< 0.05
	p21 (-)	χ4		21.8
Follow-up	Recurrent	0.0	0.094	26.7	0.51
	Non-recurrent	1.5		49.9

¹Neuroendocrine cell hyperplasia-diysplasia;

²Intestinal metaplasia;

³Mann-Whitney U test;

⁴Result is omitted since p21 value was constant in IM (-) cases.